Clinical trial
Biological Therapy in Treating Patients With Prostate Cancer
NCT00002637 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT00002637 |
|---|---|
| Title | Biological Therapy in Treating Patients With Prostate Cancer |
| Official title | PHASE I/II STUDY OF IMMUNIZATION WITH MHC CLASS I MATCHED ALLOGENEIC HUMAN PROSTATIC CARCINOMA CELLS ENGINEERED TO SECRETE INTERLEUKIN-2 AND INTERFERON-GAMMA |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Biological |
| Interventions | aldesleukin, gene-modified tumor cell vaccine therapy, recombinant interferon gamma |
| Enrollment | 25 |
| Start date | Jan 1, 1995 |
| Primary completion | Feb 1, 2001 |
| Completion | Feb 1, 2001 |
| First posted | Jun 10, 2004 |
| Last update posted | Jun 25, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: